Novo Nordisk A/S

Most Recent

  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Consistent Performance Measurement May Improve Novartis’s R&D

    Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///revenue growth
    Earnings Report

    Analyzing Novo’s Revenue Growth in 3Q16

    During 3Q16, Novo Nordisk’s (NVO) net sales rose 2.8% to 27.5 billion Danish kroner from 26.8 billion Danish kroner in 3Q15.

    By Jillian Dabney
  • uploads///new generation insulin
    Earnings Report

    How Much Did the New Generation Insulin Fetch for Novo in 1Q16?

    During 1Q16, NVO generated ~77% of its total revenue from its diabetes portfolio. New generation insulin includes sales from Tresiba, Xultophy, and Ryzodeg.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    What Do Analysts Recommend for Pfizer?

    Pfizer reported EPS of $0.67 on revenue of $13.0 billion in 1Q16 against the estimated $0.56 on revenue of $12.1 billion in 1Q16.

    By Mike Benson
  • uploads///Actual Vs Estimate
    Earnings Report

    Why Novo Nordisk Fell after Its 4Q15 Earnings Release

    After the announcement of Novo Nordisk’s earnings for 4Q15 and fiscal 2015, the stock tumbled by ~6%.

    By Jillian Dabney
  • uploads///syringe _
    Earnings Report

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.

    By Mike Benson
  • uploads///eurozone consumer confidence
    Macroeconomic Analysis

    Eurozone Consumer Confidence Unmoved by Greek Crisis, VGK Rises 2.33%

    Eurozone consumer confidence is steady in June despite the ongoing debt crisis in Greece.

    By Surbhi Jain
  • uploads///valuation
    Company & Industry Overviews

    How Sanofi’s Valuation Compares

    Sanofi (SNY) has recently been working on expanding its product portfolio in areas with potential growth and strong margins.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Focusing on These Strategic Areas in 2016

    With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

    By Margaret Patrick
  • uploads///hemophilia
    Earnings Report

    How Did Novo’s Biopharmaceuticals Segment Perform in 3Q16?

    Novo’s (NVO) Biopharmaceuticals segment rose 5.2 billion Danish kroner during 3Q16.

    By Jillian Dabney
  • uploads///drug _
    Earnings Report

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Biogen’s Hemophilia Drugs Continue to Capture Market Share in 1Q16

    Biogen’s hemophilia drugs, Alprolix and Eloctate, continued to capture market share in 1Q16.

    By Margaret Patrick
  • uploads///sales Q segmentwise
    Earnings Report

    How Did Novo’s 2 Segments Perform in 1Q16?

    Novo Nordisk’s two business segments are diabetes and obesity care and biopharmaceuticals. In 1Q16, they saw annual sales growth of 6% and 15%, respectively.

    By Jillian Dabney
  • uploads///NOK Oct
    Macroeconomic Analysis

    Norwegian Krone Extended Appreciation Trend Last Week

    The Norwegian krone appreciated against the US dollar on October 9, 2015, as a result of positive inflation data.

    By David Meyer
  • uploads///business segments
    Company & Industry Overviews

    Why Are Novo Nordisk’s Two Segments Growing?

    Novo Nordisk (NVO) operates in two major segments: diabetes and obesity care and biopharmaceuticals. Diabetes care has been Novo’s major business area.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Continues to Be a Leader in the Global Insulin Market

    Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

    By Margaret Patrick
  • uploads///DKK Nov
    Macroeconomic Analysis

    Danish Krone Fell and Inflation Was below the Forecasts

    The Danish krone fell against the US dollar on November 10, 2015. The inflation figures for October were below the expectations.

    By David Meyer
  • uploads///pill _
    Company & Industry Overviews

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

    By Sarah Collins
  • uploads///toujeo
    Company & Industry Overviews

    Sanofi Announces Positive Study Results for Toujeo

    On June 25, Sanofi (SNY) announced positive results for BRIGHT, a study comparing Sanofi’s Toujeo with Novo Nordisk’s (NVO) Tresiba (degludec).

    By Sarah Collins
  • uploads///Alliance in companeis based in US Japan
    Company & Industry Overviews

    Multinational and Japanese Pharmaceuticals Should Build Alliances

    The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

    By Jillian Dabney
  • uploads///hemophilia drugs
    Company & Industry Overviews

    What Are the Current Treatment Options for Hemophilia?

    Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

    By Jillian Dabney
  • uploads///Asset Size and Expense Ratio of Some International MFs
    Macroeconomic Analysis

    Analysis of International Mutual Funds: Investor Takeaways

    For investors interested in international mutual funds, the next step is to evaluate the investment style, as well as risk and return metrics like the Sharpe ratio and standard deviation.

    By David Ashworth
  • uploads///Saxendra
    Company & Industry Overviews

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY growth.

    By Daniel Collins
  • uploads///Chart  NVO
    Company & Industry Overviews

    Novo Nordisk Stock Performance in 1Q18

    Wall Street analysts estimate that Novo Nordisk (NVO) stock will increase 21.7% over the next 12 months.

    By Mike Benson
  • uploads///sek
    Macroeconomic Analysis

    Swedish Krona and Danish Krone Depreciate after Inflation Reports

    The Swedish krona depreciated against the US dollar by more than 1% on December 10, 2015, as inflation levels released below estimates for November.

    By David Meyer
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • uploads///biopharmaceuticals revenue mix
    Company & Industry Overviews

    What Are the Prospects for Novo’s Biopharmaceuticals Segment?

    Novo’s (NVO) biopharmaceuticals segment sales grew by 6% on a reported basis to amount to 11.8 billion Danish kroner during 1H16.

    By Jillian Dabney
  • uploads///syringe _
    Company & Industry Overviews

    Analysts See a 9.5% Upside for SNY Stock over the Next Year

    Of the five analysts covering SNY stock on June 27, two recommended “strong buy,” and three recommended “hold.”

    By Sarah Collins
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    What Analysts Expect from Pfizer in the Years to Come

    Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Novartis’s Financial Guidance and Priorities for 2017

    Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.

    By Mike Benson
  • uploads///Chart  OtherDev
    Earnings Report

    Behind Pfizer’s Corporate and Pipeline Developments in 3Q17

    In October, Pfizer announced that it’s reviewing strategic alternatives, including full or partial separation through sale or a spin-off of its consumer healthcare business.

    By Mike Benson
  • uploads///anr
    Earnings Report

    What Do Analysts Recommend for Novo?

    Danish company Novo Nordisk (NVO) released earnings for 3Q16 on October 28, 2016.

    By Jillian Dabney
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Consumer

    Renaissance Technologies: Top Investments

    Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.

    By Rabindra Samanta
  • uploads///diabetes _
    Company & Industry Overviews

    How NVO’s Revenues Are Trending in Fiscal 2019

    Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    What Analysts Recommend for GlaxoSmithKline and Novo Nordisk

    GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Sanofi Stock Up 2.8% in September: What Lies Ahead?

    On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

    By Sarah Collins
  • uploads///business _
    Miscellaneous

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Sandoz in Q2 2018

    Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.

    By Mike Benson
  • uploads///Biopharmaceuticals
    Company & Industry Overviews

    Novo Nordisk’s Biopharmaceuticals Segment: An Update

    Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018.

    By Daniel Collins
  • uploads///Premix insulin
    Company & Industry Overviews

    How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018

    Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY growth in local currencies in the first half of 2018.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.

    By Mike Benson
  • uploads///Fast acting
    Company & Industry Overviews

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, a ~2% YoY growth.

    By Daniel Collins
  • uploads///Long acting
    Company & Industry Overviews

    Novo Nordisk’s Long-Acting Insulins: A Performance Overview

    Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) had net revenues of 54.3 billion Danish kroner in H1 2018 compared to 57.1 billion Danish kroner in H1 2017.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Novartis’s Q2 2018 Earnings: Sandoz

    Sandoz, the generics arm of Novartis (NVS), reported nearly flat revenues at ~$2.46 billion during Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///GLP
    Company & Industry Overviews

    NVO’s Victoza and Ozempic Could See Steady Growth in 2018

    In June, Novo Nordisk presented the post hoc analysis of the SUSTAIN 7 trial.

    By Daniel Collins
  • uploads///premix and fast acting
    Company & Industry Overviews

    The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin

    Novo Nordisk’s human insulin generated revenues of 2.37 billion Danish kroner in Q1 2018, compared with 2.5 billion Danish kroner in Q1 2017, reflecting an ~6.0% YoY decline.

    By Daniel Collins
  • uploads///Semaglutide
    Company & Industry Overviews

    Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

    In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial.

    By Daniel Collins
  • uploads///diabetes
    Company & Industry Overviews

    A Look at Novo Nordisk’s Financial Position

    Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.

    By Daniel Collins
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///NVS NVO
    Miscellaneous

    NVS and NVO: Which Has Higher Upside Potential?

    Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline’s Pharmaceutical Business in 1Q18

    GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products.

    By Mike Benson
  • uploads///Victoza
    Company & Industry Overviews

    Novo Nordisk’s Victoza Could See High Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner.

    By Daniel Collins
  • uploads///Modern Insulin
    Company & Industry Overviews

    A Review of Novo Nordisk’s Modern Insulin

    In 4Q17, Novo Nordisk’s (NVO) modern insulins generated revenues of 10.4 billion Danish kroner.

    By Daniel Collins
  • uploads///New generation insulin
    Company & Industry Overviews

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

    By Daniel Collins
  • uploads///Xultophy
    Company & Industry Overviews

    Novo Nordisk’s Xultophy Expected to See High Growth in 2018

    In fiscal 2017, Novo Nordisk’s (NVO) Xultophy had revenues of 729 million Danish kroner compared to 207 million Danish kroner in 2016.

    By Daniel Collins
  • uploads///Tresiba
    Company & Industry Overviews

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Business in 4Q17

    Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Other Products Portfolio Performed in 4Q17

    AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Revenues Trended in 4Q17

    AstraZeneca (AZN) reported 2% growth in operating revenues to ~$5.8 billion during 4Q17 as compared to the revenues of ~$5.6 billion during 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Semaglutide May Prove to Be an Effective Anti-Obesity Therapy

    Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion May Boost Xultophy’s Sales in 2018

    In November 2017, Novo Nordisk (NVO) submitted an application to European regulatory authorities to update Xultophy’s label.

    By Margaret Patrick
  • uploads///doctor _
    Company & Industry Overviews

    Saxenda May Continue to Lead in the Diabetes Segment in 2018

    In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Xultophy May Prove a Strong Growth Driver for NVO in 2018

    Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Has Developed a Portfolio of New-Generation Insulins

    Novo Nordisk has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among general practitioners and primary care physicians.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits

    Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Tresiba Emerged as a Blockbuster Therapy in 2017

    In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will NVO Continue to Lead the Global Insulin Market in 2018?

    Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care

    According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Diabetes Care Segment Continues to Drive Growth for NVO in 2018

    According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Oral Semaglutide May Drive Solid Growth for NVO Going Forward

    On February 22, 2018, Novo Nordisk (NVO) announced the results of its 26-week Phase 3a trial, PIONEER 1.

    By Margaret Patrick
  • uploads///Strensiq
    Company & Industry Overviews

    Alexion Pharmaceuticals: Strensiq and Kanuma in 2017

    In 4Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of $95.6 million, which reflected ~35% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analyst Ratings and Recommendations for Sanofi

    In 4Q17, Sanofi reported earnings per share of 1.06 euros on revenues of 8.7 billion euros.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Victoza Continues to Lead in the GLP-1 Segment in 2018

    In 3Q17, Novo Nordisk managed to update Victoza’s label in the United States and Europe.

    By Margaret Patrick
  • uploads///woman _
    Company & Industry Overviews

    GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk

    According to IQVIA, glucagon-like peptide products currently account for only a 12% share of the global diabetes care market by value.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Sanofi’s Established Prescription Products in 4Q17

    Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Performance of Sanofi’s Business Segments in 4Q17

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Expected to Report Flat Revenue in 2018

    Flat revenue performance In its 4Q17 earnings conference call, Novo Nordisk (NVO) has projected sales to be 2%–5% higher YoY (year-over-year) in 2018 in local currency. However, the company also anticipates a seven-percentage-point impact due to unfavorable currency fluctuations, which could impact its revenue growth rate. The company accounts for 27% of the global diabetes care market and […]

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    Analysts’ Recommendations for Novo Nordisk and Peers in 2018

    Novo Nordisk (NVO) reported sales of ~112 billion Danish kroner in fiscal 2017.

    By Margaret Patrick
  • uploads///ablynx sanofi partnership
    Company & Industry Overviews

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

    By Sarah Collins
  • uploads///ABLYNX_TRANSACTION_HIGHLIGHTS
    Company & Industry Overviews

    Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition

    On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

    By Sarah Collins
  • uploads///PROPHYLAXIS
    Company & Industry Overviews

    Sanofi Leads the Hemophilia Space on Bioverativ Acquisition

    According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

    By Sarah Collins
  • uploads///Chart  Ratings
    Earnings Report

    Analysts’ Recommendations for Novartis after Its 4Q17 Earnings

    Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Sandoz Business

    Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Segment-Wise Revenues

    Novartis (NVS) reported revenues of ~$12.9 billion in 4Q17, representing 5.0% growth in revenues compared to ~$12.3 billion in 4Q16.

    By Mike Benson
  • uploads///Ablynx
    Company & Industry Overviews

    How Sanofi Can Benefit from Ablynx Acquisition

    On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.

    By Daniel Collins
  • uploads///Chart  Alcon
    Earnings Report

    Reading the Estimates for Novartis’s Alcon in 4Q17

    For 4Q17, Alcon is expected to report growth in revenues, driven by the increased demand for contact lenses and surgical products.

    By Mike Benson
  • uploads///Chart  Sandoz
    Earnings Report

    What’s Expected of Novartis’s Sandoz Segment in 4Q17?

    Sandoz’s positive revenue growth in 4Q17 is expected to be driven by strong sales in European markets and the rest of the world (excluding the US).

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.

    By Mike Benson
  • uploads///Chart  Segment Revenues
    Earnings Report

    Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth

    Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.

    By Mike Benson
  • uploads///Eloctate
    Company & Industry Overviews

    How Is Bioverativ’s Eloctate Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.